Rivaroxaban News and Research

RSS
New blood-thinning drugs likely to replace Coumadin for patients with non-valvular AF

New blood-thinning drugs likely to replace Coumadin for patients with non-valvular AF

New drug might effectively prevent clot-related strokes in patients with AF

New drug might effectively prevent clot-related strokes in patients with AF

Occasional erratic heart rhythms cause about one-fifth of unexplained strokes

Occasional erratic heart rhythms cause about one-fifth of unexplained strokes

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

Enrollment complete in ThromboGenics, BioInvent TB-402 Phase IIb trial on VTE

Enrollment complete in ThromboGenics, BioInvent TB-402 Phase IIb trial on VTE

Xarelto (rivaroxaban) shows success as blood thinner in acute coronary syndrome

Xarelto (rivaroxaban) shows success as blood thinner in acute coronary syndrome

Bayer and J&J’s blood thinner drug triumphs at late phase clinical trial

Bayer and J&J’s blood thinner drug triumphs at late phase clinical trial

BIDMC researcher says improvement in survival rates best 'since introduction of aspirin'

BIDMC researcher says improvement in survival rates best 'since introduction of aspirin'

Janssen receives FDA approval for Xarelto to prevent stroke in people with AF

Janssen receives FDA approval for Xarelto to prevent stroke in people with AF

FDA panel votes 9-2 in favor of new blood thinner drug

FDA panel votes 9-2 in favor of new blood thinner drug

Cardiovascular and Renal Drugs Advisory Committee recommends FDA approval of J&JPRD's rivaroxaban

Cardiovascular and Renal Drugs Advisory Committee recommends FDA approval of J&JPRD's rivaroxaban

FDA stalls the blood-thinner Xarelto’s approval citing inadequate evidence

FDA stalls the blood-thinner Xarelto’s approval citing inadequate evidence

Arrythmia drug may work in stroke prevention: Study

Arrythmia drug may work in stroke prevention: Study

Johnson & Johnson second quarter sales increase 8.3% to $16.6 billion

Johnson & Johnson second quarter sales increase 8.3% to $16.6 billion

Mortality, morbidity rates linked with AF remain 'unacceptably high' despite new treatments

Mortality, morbidity rates linked with AF remain 'unacceptably high' despite new treatments

BioInvent, ThromboGenics initiate TB-402 Phase IIb trial for VTE prophylaxis

BioInvent, ThromboGenics initiate TB-402 Phase IIb trial for VTE prophylaxis

J&JPRD announces rivaroxaban Phase 3 trial results against venous thromboembolism

J&JPRD announces rivaroxaban Phase 3 trial results against venous thromboembolism

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Apixaban drug raises hope for DVT prevention in patients undergoing hip replacement surgery

Apixaban drug raises hope for DVT prevention in patients undergoing hip replacement surgery

J&JPRD submits New Drug Application to FDA for rivaroxaban

J&JPRD submits New Drug Application to FDA for rivaroxaban